Company Overview of Watson Laboratories, Inc.
Watson Laboratories, Inc. manufactures pharmaceutical drugs. The company was incorporated in 1992 and is based in Corona, California. Watson Laboratories, Inc. operates as a subsidiary of Allergan plc.
132 Business Center Drive
Corona, CA 92880-1724
Founded in 1992
Key Executives for Watson Laboratories, Inc.
Watson Laboratories, Inc. does not have any Key Executives recorded.
Watson Laboratories, Inc. Key Developments
Cipher Pharmaceuticals Announces Outcome of Markman Hearing in Patent Infringement Suit for Absorica®
Apr 24 15
Cipher Pharmaceuticals Inc. announced that the Court has issued an opinion in the claim construction hearing (commonly referred to as a "Markman hearing") for the patent infringement suit by Ranbaxy Inc., Ranbaxy Pharmaceuticals Inc., Galephar Pharmaceutical Research Inc., and Cipher against Watson Laboratories, Inc. ("Watson", now Actavis plc) related to Watson's Abbreviated New Drug Application (ANDA) for a generic version of Absorica® (isotretinoin capsules). The purpose of a Markman hearing is to determine the precise meaning of words from patent claims that are in dispute in a patent infringement lawsuit. No ultimate determination of infringement or validity of the patents has been determined at this point.
Federal Trade Commission Approves Final Order Preserving Future Competition in Generic Injectable Tuberculosis Drug Market
Sep 19 14
Federal Trade Commission has approved a final order settling charges that Akorn, Inc.'s acquisition of VersaPharm Inc. and its parent company, VPI Holdings Corp., would have likely been anticompetitive. Under the order, first announced in August 2014, Akorn is required to divest its Abbreviated New Drug Application for generic injectable rifampin - which is currently pending before the Food and Drug Administration - to Watson Laboratories, Inc. According to the FTC's complaint, only VersaPharm and two other firms currently have FDA approval to sell generic injectable rifampin. There are no viable substitutes for rifampin as a course of treatment for tuberculosis. The FTC alleged that if Akorn had consummated its acquisition of VersaPharm as originally proposed, the combined company would have been likely to delay or cancel the introduction of Akorn's generic injectable rifampin.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries